S. Wang

机构：Hebei Medical University, Central South University, Sun Yat-sen University, Fourth Hospital of Hebei Medical University, Xiangya Hospital Central South University · ORCID：0000-0001-9744-9717

发表论文 32 篇 · 总被引 188 次 · h-index 7

代表论文

• LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial (2023 · Annals of Oncology · 被引 42)
• LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial (2025 · Annals of Oncology · 被引 26)
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer (2024 · ESMO Open · 被引 19)
• LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial (2022 · Annals of Oncology · 被引 18)
• 228MO PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC) (2021 · Annals of Oncology · 被引 10)
• LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): Additional safety analysis from TROPION-Breast01 (2024 · ESMO Open · 被引 9)